COVID Vaccine Chart Updated July 16, 2021

Vaccine Name Comirnaty mRNA-1273 Johnson & Johnson NVX-CoV2373 Covishield/Vaxzevria Sputnik V CVnCoV BBIBP-CorV CoronaVac Manufacturer Pfizer-BioNTech Moderna Janssen Pharmaceutica Novavax Oxford-AstraZeneca Gamaleya CureVac N.V. & CEPI Sinopharm Sinovac Biotech MOA mRNA vaccine mRNA vaccine Adenovirus vector vaccine Protein-based vaccine Adenovirus vector vaccine Adenovirus vector vaccine mRNA vaccine Inactivated coronavirus Inactivated coronavirus Dosing 2 doses, two to four weeks 2 doses, 21 days apart 2 doses, 28 days apart 1 dose 2 doses, one month apart 2 doses, three months apart Sputnik Light requires one dose. 2 doses, four weeks apart 2 doses, three weeks apart Schedule apart In a press release, the Gamaleya National Vaccine demonstrated Center of Epidemiology and Microbiology in 100% protection against Moscow claimed a large-scale Russian moderate and severe study saw 92% efficacy for its vaccine. June 16, 2021 update: disease, 90.4% efficacy However, other scientists have voiced Preliminary analysis of CureVac's Approxomiately 50% according 76% in a U.S. study against 72% in the U.S. and 66% globally overall, and met the primary concerns this claim is based on too few Phase 3 trial showed a 47% to Sinovac's Phase 3 trial. D symptomatic COVID-19; 100% 94.1% at least 14 days against moderate-to-severe disease; endpoint in its PREVENT- cases. Although the vaccine was trialled on efficacy rate. Researchers have 78% according to the World Health However, real-world 95% at least 7 days after dose 2 effective severe disease; 85% e Efficacy after dose 2 85% effective against severe 19 pivotal Phase 3 trial. 18,000 people, the efficacy claim has been since noted that the vaccine Organization effectiveness has been shown efficacy against symptomatic disease, 28 days after a single dose. June 30, 2021 update: based on an analysis of only 39 individuals dosage may have been a factor to be approximately 67%. t COVID-19 in those 65+ Results from the Phase 3 to test positive with coronavirus. Update leading to low efficacy; CureVac a trial in the UK indicate an (June 2021) The Russian Direct Investment still plans to appy for EUA. i overall vaccine efficacy rate Fund announces that Sputnik Light l of 89.7%. demonstrated 78.6-83.7% efficacy amongst the elderly population in Argentina. s Ultra-cold freezer required, for up to 6 months. Update (May 2021): undiluted, thawed Pfizer- BioNTech COVID-19 Vaccine Frozen; can be stored Stable at regular fridge temperature vials to be stored in the refrigerated for up to for up to 3 months and stable for 2 Stable in refrigerator for at least Sputnik Light is refrigerator stable at 36.5 - Refrigerator stable at 36.5-46.4 Regular fridge temperature Stable in refrigerator for 3 months Refrigerator stable at 36.5 - 46.4ºF. Storage refrigerator at 2°C to 8°C (35°F to 30 days prior to first years at -4ºF. Update (June 2021) 6 months 46.4ºF. ºF. 46°F) for up to 1 month. use. FDA extends shelf life by 6 weeks. Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to 5 days. Phase 3 trial in progress, U.S. EUA Dec 11, 2020 Dec 18, 2020 Feb 27, 2021 EUA date delayed to July at delayed, but in progress A the earliest. u U.S. FDA submitted for approval submitted for approval t U.K. EUA Dec 2, 2020 Jan 8, 2021 May 28, 2021 In progress Dec 30, 2020 h E.U. EUA Dec 21, 2020 Jan 6, 2021 Mar 11, 2021 *exploratory talks Jan 29, 2021 pending o Russia Nov 2020 r Canada Dec 23, 2020 i W.H.O. May 7, 2021 June 1, 2021 z March 2021: PAUSED - Some a EU countries decided to restrict the use of AstraZeneca's t 4/13/2021: PAUSED out of vaccine to older citizens after i "abundance of caution" due to blood cases of blood clots were clot and low platelet reports assessed in younger people. o Countries include France, n Germany, and Denmark, amongst others. 4/23/2021: pause lifted March/April 2021: pause lifted Granted EUA by the WHO for Authorized for ages 12+ by the Authorized for ages A Authorized for ages 18+, with ages 18+. FDA, EMA and The Medicines 18+, pending EUA for Granted EUA by the WHO for ages Authorized for ages 18+. age limitations in EU certain Approved for ages 18+. Endorsed in China for ages 3+ g and Healthcare Products adolescents 12-17 18+. countries. (approval has not been officially e Regulatory Agency in the UK. years of age. announced).

3/16/2020: Moderna begins Phase 1 human January 2020: Sinovac begins Q1 2020 clinical trial for their developing a vaccine using an mRNA COVID-19 inactivated coronavirus strain. vaccine in the U.S.

4/29/2020: Human trials begin in 4/29/2020: Researchers begin Phase Q2 2020 Germany. 1 trial. 5/12/2020: Moderna receives Fast Track designation from the FDA to proceed with a Phase 2 study of their vaccine. 5/1/2020: Novavax 5/18/2020: Moderna announces a combined releases interim data Phase 1/2 clinical trial, with May 2020: CureVac announces 5/5/2020: Pfizer and BioNtech from their Phase 1 phase 1 starting in Austraia positive results for vaccine Dose 1st U.S. Participants. clinical trial, stating and Phase 2 to be candidate in preclinical plans for a Phase 3 conducted in multiple expieriments. trial to begin in July. countries following the 5/29/2020: Moderna results of Phase 1. announces purpose and enrollment of Phase 2 clinical trial. Enrollment was completed July 8.

D e v e l o p m e n t

H i g h l i g h t s Vaccine Name Comirnaty mRNA-1273 Johnson & Johnson NVX-CoV2373 Covishield/Vaxzevria Sputnik V CVnCoV BBIBP-CorV CoronaVac Manufacturer Pfizer-BioNTech Moderna Janssen Pharmaceutica Novavax Oxford-AstraZeneca Gamaleya CureVac N.V. & CEPI Sinopharm Sinovac Biotech 6/6/2020: Researchers confirm June 2020: The Gamaleya Research promising results from trial in Institute begins clinical trials for a monkeys, stating the vaccine is combination adenovirus vaccine. genetically stable and seems to be safe in animals. 7/14/2020: Moderna publishes interim July 2020: China launches results of their Phase 1 7/20/2020: AstraZeneca's vaccine program to distribute trial in The New 7/30/2020: Single dose of J&J Phase 1 human clinical trial Sinovac, Sinopharm and 7/18/20: Phase 3 trial begins in the England Journal of vaccine candidate demonstrates results are published in The Cansino Covid-19 vaccines UAE, with subsequent Phase 3 trials Q3 2020 Medicine. robust protection in pre-clinical Lancet; results show vaccine is within China. Phase 3 testing in Peru and Morocco. 7/27/2020: Moderna studies. safe and create an immune was not complete at the time. begins Phase 3 clinical response. Additional trials launched in trial, enrolling 30,000 Brazeil, Indonesia, and Turkey. adults across the U.S. 8/4/2020: Novavax announces the results of Phase 1 of the Phase 1/2 8/10/2020: Results of a Phase clinical trial stating the 1/2 trial are published stating no vaccine was "generally well- safety concerns were observed 8/12/2020: Peer-Reviewed Phase tolerated and elicited robust amonst 743 volunteers. Adverse 1/2 Data Published in Nature antibody responses." events were mild in severity, Magazine. 8/24/2020: Novavax and primarily isolated to pain at announces the initation of the injection site. The results Phase 2 of its Phase 1/2 have not been peer reviewed. clinical trials. Participants are enrolled in both the U.S. and Australia. 9/3/2020: Vaccine prevents severe clinical disease in pre-clinical studies. 9/23/2020: Global Phase 3 'Ensemble' Clinical 9/2/2020: Novavax Trials begin. announces publication of 9/25/2020: Interim results from Phase 1 results in The New Phase 1/2a clinical trial support England Journal of 9/4/2020: The Gamaleya Research Institute further clinical development of Medicine. publishes the results of their Phase 1/2 9/1/2020: Phase 3 clinical trials vaccine, but Phase 3 PAUSED after 9/24/2020: Novavax clinical trial, announcing their Sputnik V begin in the U.S. D a serious medical event experienced announces initiation of vaccine yielded antibodies with only mild e by 1 study participant. Phase 3 clincial trial using side effects. 9/25/2020: Interim results from 10,000 participants across v Phase 1/2a clinical trial support the U.K. (enrollment is e further clinical development of completed 11/30/2020). vaccine, but Phase 3 PAUSED after l a serious medical event experienced o by 1 study participant. p 10/17/2020: Research published in m The Lancet shares the results of a 10/19/2020: Officials in Brazil 10/23/2020: Phase 3 Ensemble Trial 10/17/2020: Phase 2/3 trial launches in Phase 1/2 trial, showing the vaccine quote Sinovac's vaccine as e Q4 2020 resumes. India. stimulates the production of antibodies being the safest of five being n and does not cause serious adverse tested in Phase 3 trials. t effects. 11/23/2020: AstraZeneca and 11/16/2020: Moderna the University of Oxford releases preliminary announce the initial results of 11/11/2020: The Russian Direct Investment H 11/18/20: Pfizer and BioNTech data from Phase 3 11/16/2020: Announcement of the Phase 3 clinical trials in the Fund announces that Sputnik's Phase 3 November 2020: CureVac reports November 2020: Sinopharm reports 11/17/2020: Sinovac publishes i conclude Phase 3 Study, meeting clinical trial, stating second Phase 3 clinical trial to U.K., Brazil, and South Africa. clinical trial demonstrated high efficacy positive interim Phase 1 data for that over 1 million doses have been the results of their Phase 1/2 all primary and secondary their vaccine is 94.5% observe the use of two doses versus g The study showed the vaccine rates, determining a 92% efficacy rate for its COVID-19 vaccine candidate. administered to the public. trial in The Lancet. efficacy endpoints. effective. The data is one. was safe and effective. Data the Sputnik V vaccine. h released in full on from the study was published November 30. l 11/19 in The Lancet. i 12/2/2020: Moderna g files to test their vaccine in adolescents h 12-18 years of age. December 2020: The Gamaleya Reserch 12/23/2020: CureVac begins 12/23/2021: Brazil announces t 12/10/20: Pfizer and BioNTech Moderna announces 12/28/2020: Novavax Institute and AstraZeneca decide to Phase 3 trial using 36,500 that CoronaVac has an efficacy s Announce Publication of Results the clinical trial on announces initiation of combine vaccines in an effort to increase participants across Europe and 12/30/2020: Sinopharm states their rate of over 50%.12/24/2021: from Phase 3 Trial in The New March 10, 2021. Phase 3 efficacy trial in U.S. the efficacy of the AstraZeneca vaccine, Latin America. Results are vaccine has an efficacy rate of 79%. Turkey announces that the England Journal of Medicine. 12/31/2020: Moderna and Mexico. with clinical trials beginning in February presumed to be released in May vaccine has an efficacy rate of publishes results of 2021. 2021. over 91%. Phase 3 trial in The New England Journal of Medicine. 1/7/2021: Researchers in Brazil specify that the CoronaVac 1/13/2021: Interim Phase 1/2a Data 1/13/2021: Interim Phase vaccine has an efficacy rate of published in New England Journal of 1/2a Data published in New 78% and prevents severe Medicine. England Journal of disease. This figure was based 1/29/2021: Johnson & Johnson Medicine. on the results of a volunteer Q1 2021 announce that their Phase 3 trial January 2021: Novavax subgroup; the efficacy rate was show their vaccine to be safe and announces that vaccine not officially released. effective; the results of the trial are demonstrated 96% efficacy 1/13/2021: Brazilian published in The New England in a 15,000 person trial in researchers backtrack and Journal of Medicine April 29, 2021. Britain. announce that the CoronaVac actually has an efficacy rating of just over 50%. D e v e l o p m e n t

H i g h l i g h t s

5/5/2021: Researchers at Pfizer and Israel’s Ministry of Health 5/6/21: Moderna 5/3/2021: Novavax expands observe Pfizer vaccine to be over announces that Phase 3 trial to include 95% effective against infection, vaccine is 96% children ages 12+. 5/28/2021: CureVac releases 5/7/2021: The World Health hospitalization and death against effective in preventing 5/21/2021: Novavax statement verifying that an Organization states that Sinopharm's the B.1.1.7 variant amongst infection in children announces its participation 5/6/2021: The Russian government independent Data Safety vaccine has an efficacy rate of 78%, Israel’s vaccinated population. 12+. in a UK mix-and-match authorizes Sputnik Light for use after their Monitoring Board found the and authorizes it for emergency use. 5/13/2021: Sinovac begins The results of the study are 5/28/2021: Moderna booster trial alongside 6 Ministry of Health announces Sputnik Light vaccine to be safe; they are The results of the Phase 3 trial have Phase 2 clinical trial on children published in The Lancet. begins Phase 1/2 other vaccine is 79.4% effective. Details of the study are waiting to release further not yet been released. 3-17 years old. 5/25/21: Pfizer begins Phase 3 clinical trial on the use manufacturers. The study not released. information regarding the trial, to 5/23/2021: UAE announces they will trial using their pnuemococcal of the Moderna will include participants who include efficacy data, by the end of distribute a third booster shot of the vaccine candidate in conjunction vaccine as a booster have previously been June. vaccine. with the Pfizer Covid-19 vaccine shot to a range of other vaccinated with 2 doses of as a booster in adults 65+. vaccine brands. an authorized vaccine.

6/14/2021: Novavax releases the results of their Phase 3 clinical trial in the US and Mexico, stating their vaccine is 90.4% effective overall, with 100% efficacy against moderate and 6/8/2021: Pfizer announces 6/16/2021: Following the Phase 6/28/2021: Sinovac publishes 6/29/2021: Moderna severe disease. advancement of Phase 2/3 2b/3 study (40,000 subjects), the results of a Phase 1/2 announces that a full 6/30/2021: Novavax 6/2/2021: The Russian Direct Investment 6/3/2021: Bahrain announces clinical trials in children ages 5- CVnCoV demonstrated an interim clinical trial testing their Covid- dose of their vaccine publishes the results of their Fund announces that Sputnik Light distributing a third booster shot. 11. 6/28/2021: A study published vaccine efficacy of 47% against 19 vaccine in youths ages 3-17. provides protection Phase 3 trial in the New demonstrated 78.6-83.7% efficacy amongst 6/10/2021: UAE begins testing in in Nature confirms the Pfizer COVID-19 disease of any severity The study demonstrated high against the delta, eta England Journal of the elderly population in Argentina. children ages 3-17. vaccine is highly effective against and did not meet prespecified immunogenicity and safety and kappa variants. Medicine. The trial was variants, including delta. statistical success criteria. levels. conducted in the UK and showed an overall vaccine efficacy rate of 89.7%. The vaccine showed 96.4% efficacy against non-B.1.1.7 variants, which parallel strains of the original virus. 7/1/2021: Johnson & Johnson 7/8/2021: Pfizer announces the releases a statement addressing the 7/14/2021: Sinovac begins development of a new delta variant, saying the vaccine recruiting for clinical trial testing coronavirus vaccine that offers effective protection. They have the efficacy of a booster shot. Q3 2021 specifically targets the Delta submitted a pre-print of data from the Participants will include those variant; clinical trials are expected laboratory study to bioRxiv, further 18-59 years of age. to begin next month. citing that immunity from the vaccine lasts at least 8 months.